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ABSTRACT 
EFFECT OF ANTIGENIC SITE MUTATIONS ON THE BINDING SPECIFICITY OF 
AN ANTI-HEMAGGLUTININ ANTIBODY TO H3N2 INFLUENZA VIRUS 
ISOLATES 
By 
 
Juliana Liambaya Hagembe 
 
The hemagglutinin (HA) is the main antigenic glycoprotein found on the surface of the 
influenza virus and contains a sialic acid receptor-binding site that allows binding of the 
virus to a host cell. This important role makes it an ideal target for neutralizing 
antibodies.  However, its ability to mutate and change every year at antigenic sites reduce 
or inhibit the binding of anti-hemagglutinin neutralizing antibodies, thereby allowing new 
subtypes to spread within non-immune species. Understanding the effect mutations of 
HA to antibody binding specificity, is not only fundamental to understanding the 
biological processes but also helpful in inhibitor design through rational design. 
Molecular Dynamics simulations and Molecular Mechanics-Poisson Boltzman Surface 
area (MM-PBSA) free energy calculations were used to study and compare the energetics 
of the binding of HAs from seven, Hong Kong, influenza, H3N2 Isolates from 1968, 
1969, 1974, 1975, 1985, 1992, 1999 to the A/AICHI/68 (H3N2) anti-HA antibody. This 
study provides a bit more insight on the trend of mutations of HA and the route of 
evolution of influenza viruses. Results show an overall decrease in binding energy with 
increase in mutations and year progression.  In addition, the association of HA to the 
antibody is driven by highly favorable van der Waals interactions whereas solute and 
solvent electrostatic energies contributed unequally to binding.   
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INTRODUCTION 
 
 
 
 
Interactions between proteins play an essential role in many biological processes 
such as enzyme regulation, signal transduction and immune response. The binding of two 
structurally different proteins to a similar surface has been described on several 
occasions. Some of the interactions studied concern complexes between antigen and 
antibody where one of the wild-type molecular partners is able to bind to structural 
variants of the other: in most cases, these wild-type counterparts are formed by proteins 
with only a few amino acids difference 1-3. Understanding how protein complexes form 
and what determines their specificity, binding constants and substitutions is not only 
fundamental to biological interpretation of the processes but also helpful in inhibitor 
design through a rational approach 4, 5. The influenza virus, which creates multiple 
problems due to its ability to mutate and change every year, is a prime candidate for such 
a study. 
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1.1 Influenza Virus 
 
1.1 1 Influenza virus overview 
 
The influenza virus is a respiratory pathogen that causes influenza, an acute 
respiratory disease with prominent systemic symptoms. A wide variety of warm-blooded 
animals including birds, various wild and domesticated mammals and humans are 
vulnerable to infection by the virus. In humans, in addition to the symptoms directly 
attributable to infection by the influenza virus, the patient will also be at risk for 
complications such as the onset of pneumonia 6. This is a particularly serious 
complication for the elderly and others with immuno-compromised systems. Today, 
pneumonia and influenza are listed as leading causes of death in the United States, 
responsible for 50,000 to 70,000 deaths annually 7. The seasonal nature of influenza, the 
ease of transmission, the high rates of fatalities that it causes among the elderly and 
among patients under 5 years of age, have made influenza a key public health concern 8. 
The Orthomyxovirus genus, to which influenza belongs, consists of three species: 
A, B, and C, each distinguished by antigenic differences in two of their stable internal 
proteins, Nucleoprotein (NP) and Matrix protein (M) 9. In addition, the viruses differ in 
their pathogenicity and genome organization.  Type A viruses are found in a wide variety 
of warm blooded animals including birds and humans and causes periodic worldwide 
epidemics (pandemics) in their host organisms, whereas types B and C are chiefly human 
pathogens and rarely cause pandemics 10. The viruses of this genus are most commonly 
spherical (filamentous forms may also occur), approximately 80 nm to 120 nm in 
diameter, and have an eight-fold segmented, single-stranded RNA genome with negative 
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polarity containing between 890 and 2341 nucleotides each.  An excellent review on the 
structure and replication strategy of influenza viruses has been published recently 11. 
The virus has a core ribo-nucleoprotein that contains the genetic information of 
the virus wrapped up in protein. The eight separate viral RNA segments of the antisense 
RNA of both the influenza A and B virus  (Figure 1), each code for a functionally 
important protein. The virus even with a fairly small genome is able to encode for a 
variety of proteins using different reading frames and alternate RNA splicing. The 
proteins encoded by the RNA segments include; Polymerase B2 protein (PB2), 
Polymerase B1 (PB1), Polymerase A (PA), Hemagglutinin (HA), Nucleocapsid protein 
(NP), Neuraminidase (NA or N) and Matrix protein (M). Each RNA segment is 
encapsulated by the NP to form the ribo-nucleoprotein (RNP) complex. 
 
 
 
 
Figure 1: A diagrammatic representation of influenza A and B virus showing protein and RNA 
composition (Polymerase B2 (PB2), Polymerase B1 (PB1), Polymerase A (PA), Hemagglutinin (HA), 
Nucleocapsid (NP), Neuraminidase (NA or N), Non structural proteins (NS), Hemagglutinin (HA), and 
Matrix protein (M)). 
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The active RNA polymerase, which is responsible for replication and 
transcription, is formed from PB2, PB1 and PA. In addition to the polymerase activity, it 
has an endonuclease activity and is linked to the ribo-nucleoprotein. The NS1 and NS2 
proteins have a regulatory function to promote the synthesis of viral components in the 
infected cell. The NP encapsulates each RNA segment thus forming a nucleocapsid. The 
nucleocapsid is surrounded by a shell of two Matrix proteins (M1 and M2).  M1 
constructs the matrix; and in influenza A viruses, M2 acts as an ion channel pump to 
lower or maintain the pH of the endosome of the infected cell. Overlying the matrix is the 
viral envelope consisting of a lipid bilayer, which has multiple copies of glycoproteins 
radiating from its surface. The characteristic rod-shaped "spikes” are HA and the 
interspersed mushroom-shaped clusters are NA. These HA and NA molecules are thought 
to pass through the envelope and interact with the underlying matrix protein.  
HA and NA are the major antigens in influenza. HA mediates the first stages of 
virus infection; sialic acid binding and virus-cell membrane fusion 12, whereas NA is 
concerned with the release of progeny virions from the cell surface 13. NA acts as an 
enzyme, cleaving sialic acid from the HA molecule, from other NA molecules and from 
glycoproteins and glycolipids at the cell surface 14. The HA and the NA are used to 
further subdivide the influenza A virus into additional subtypes 15. Currently 15 subtypes 
of HA (HI-H15) and nine subtypes of NA (N1-N9) have been discovered. The influenza 
virus continuously undergoes antigenic drift and antigenic shift to escape the host’s 
acquired immunity. The two glycoproteins are constantly subjected to selection pressure 
by the host’s defense mechanism. Antigenic drift, the accumulation of mutations in all 
influenza gene segments, is particularly prevalent in the surface glycoproteins (HA and 
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NA) 16-21.  The main cause of point mutations is thought to be due to a lack of 
proofreading ability by the RNA-dependent polymerase complex 22. Antigenic shift, on 
the other hand, occurs as a result of genetic re-assortment of the genome segments from 
different influenza viruses. Antigenic shift causes the extinction of the current strain of 
the influenza virus due to replacement of the strain specific glycoprotein’s (HA or NA) 
with new ones 23. The source and host of such new viruses is thought to be animals such 
as birds or pigs. 
 To adequately describe a particular influenza virus isolate, the influenza virus 
type, the host species (omitted in the case of human origin), the geographical site of first 
isolation, serial number and year of isolation must be mentioned. In the case of influenza 
virus type A, the nomenclature also includes HA and NA subtypes in brackets. One of the 
parental avian strains of the current outbreaks of H5N1 of Asian lineage was isolated 
from a goose in the Chinese province, Guangdong: accordingly, it is designated 
A/goose/Guangdong/1/96 (H5N1) (Xu 1999), while the isolate originating from the 
human case of Asian lineage H3N2 infection from Aichi (1968) is referred to as 
A/Aichi/68 (H3N2). 
So far only three HA subtypes and NAs from two subtypes have caused human 
pandemics: H1N1 in 1918, H2N2 in 1957 and H3N2 in 1968. Three small outbreaks have 
also arisen from avian subtypes (H5, H7, and H9). The avian subtypes managed to make 
a direct leap to humans from birds but their low transmissibility prevented major 
epidemics 24. The next expected pandemic threat at the moment is from the H5N1 (bird) 
or H1N1 (swine) virus subtype 25. 
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Vaccination is the primary method for preventing influenza and its implications. 
So far inactivated-virus vaccines have provided essential protection when the vaccine 
antigens and the circulating viruses share high degree of similarity in the HA protein. 
Since new influenza virus antigenic variants emerge frequently from accumulation of 
point mutation in the HA protein (i.e. antigenic drift), influenza vaccines need to be 
updated frequently based on the results of global influenza surveillance; including 
clinical, virological and immunological surveillance. In virological surveillance, 
influenza viruses are characterized antigenically on the basis of the ferret serum antibody 
cross- reactivity. Antigenic variants selected serologically are then tested for antibody 
cross- reactivity in human sera to evaluate the potential cross-protection against the 
antigenic variant provided by the current vaccines and to select vaccine strains for the 
next season 7, 26. 
 
1.1.2 Hemagglutinin overview 
HA is the main influenza antigenic glycoprotein found on the surface of the 
influenza viruses (as well as many other bacteria and viruses) and plays an important role 
in virus life cycle. The term "hemagglutinin” arises from the protein's ability to cause red 
blood cells (erythrocytes) to clump together ("agglutinate") in vitro. The protein contains 
a sialic acid (N-acetylneuraminic acid) binding site, which allows binding of the virus to 
the cell that is being infected. It also induces membrane fusion allowing release of viral 
RNPs in to the cellular cytoplasm 1, 27. The body of the HA molecule contains the stalk 
region and the fusiogenic domain that allows membrane fusion needed for the virus to 
enter a new cell. It consists of 562 - 566 amino acids, with a molecular weight of 
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approximately 220 kDa and has either two or three glycosylation sites 28, 29. It spans the 
lipid membrane so that the major part, which contains at least 5 antigenic domains, is 
presented at the outer surface 30.  These antigenic sites, which surround the host receptor-
binding site, are presented at the head of the molecule, while the feet are embedded in the 
lipid layer. Prominent mutations in the antigenic sites reduce or inhibit the binding of 
neutralizing antibodies, thereby allowing a new subtype to spread within a non-immune 
species 22, 31.  
 
1.1.3 Hemagglutinin Structure 
The atomic structure of HA was first published in 1981 by Wilson, Wiley and 
Skehel to a resolution of 3 Angstroms 1. This was the first look at the structure of a viral 
membrane protein. They found that HA is an elongated homotrimeric 27 integral 
glycoprotein that is shaped like a cylinder and measures 135 Å from insertion in the 
envelope membrane to its tip. 
 
 
 
 
Figure 2: Ribbon representation of HA0 trimmer 
influenza virus. Each monomer (colored 
differently) possesses two important sites: 1) The 
'Receptor binding site' for virus attachment to the 
host lung epithelial cells via sialic acid 
containing host cell receptors. 2) The 'cleavage 
site' where for full infectivity, the single chain 
(HA0) is cut into two chains (HA1 & HA2). At 
the N-terminal end of the HA2 chain is the 
fusion peptide, which is critical for subsequent 
membrane fusion events that lead to infection. 
(Image created and modified using RasMol 
[PDB 1HGF]32).  
Receptor binding site 
Cleavage 
site 
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The trimmer contains two distinct regions; a stem consisting of a triple stranded 
coiled-coil of alpha helices extending 76 Å from the membrane and a globular region of 
anti-parallel beta-sheet on top. The conserved host-receptor binding site was found to be 
located on the top globular portion. It is the amino acids that surround this region that 
have undergone change in most of the antigenic variants appearing in influenza virus 
epidemics. Each of the three monomeric subunits is synthesized as a precursor that is 
glycosylated and then cleaved into two smaller polypeptides (the HA1 and HA2 subunits). 
The six resulting chains are three HA1s and three HA2s. 
 
 
 
 
Figure 3: Ribbon diagram representation of HA 
showing the chains that result in the event of 
proteolytic cleavage of a trimmeric precursor 
protein. Three green HA1 and three red HA2’s 
(Image created and modified using RasMol 
[PDB 1HGF]).
 
 
The HA2 is a helical chain anchored in the membrane and is topped by a large 
HA1 globule. The HA1 subunit (328 residues) is an elongate structure reaching from the 
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N-terminus at the viral membrane end of the molecule along the stem of the subunit 
before forming a globular tip. It then returns part way down the stem of the monomer, 
ending at the C-terminus part of its distal end.  The HA1 subunit forms an 8-stranded anti-
parallel beta-sheet motif known as a "jelly roll."  
 
 
 
 
 
  The loop that separates the 3rd and 4th   strand of the jellyroll contains a short α-
helix. Residues from one side of this α-helix and from residues near the top of the 
jellyroll form a pocket that is the sialic acid binding site for each monomer of the 
hemagglutinin trimmer. The binding sites contain the conserved amino acids - Y98, 
W153, H183 and Y195 – that form the base of the site which is limited at the top by a 
short α-helix (the 190-helix, residues 190–198), a loop-like structure at the front edge (the 
Figure 4: HA monomer, showing 
the HA1 subunit (328 residues), an 
elongate structure reaching from 
the red N terminus at the viral 
membrane end of the molecule 
along the stem of the subunit 
before forming a globular tip and 
then returning part way down the 
stem of the monomer, ending at the 
yellow terminus tip. The long 
alpha-helix of H2 can also be seen 
(cyan). (Image created and 
modified using RasMol [PDB 
1HGF]). 
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130-loop, residues 133–138) and another loop that forms the left edge, near the 
intersubunit interface (the 220-loop, residues 220–229) 33. Antigenic sites, which 
surround the host receptor-binding site, are presented at the head of the molecule. The 
receptor-binding sites in all HAs are at the membrane distal tip of each subunit in the 
trimer.  Antigenic sites (antibody binding sites) residues in the HA1 chain, previously 
described by Brownlee and Fodor 34  are grouped into 5 regions: Ca1 (169 to 173, 208 to 
296, 238 to 240), Ca2 (140 to 145, 224 to 226), Cb (78 to 83), Sa (128 to 129, 156 to 160, 
162 to 167), and Sb (187 to 198) 
 ‘Fixed’ changes, i.e. changes retained in HAs of viruses isolated in subsequent 
years, involved residues on the surface of HA, whereas about two-thirds of those not 
retained were found to be buried. These ‘fixed’ substitutions are thought to have been 
selected because they prevent antibody binding. This hypothesis is supported by the 
coincidence of the locations of these substitutions with the locations of amino acid 
substitutions detected in antigenic variant HAs that were selected by growing virus in the 
presence of monoclonal anti-HA antibodies 12, 35.  
A notable feature of the HA2 subunit (221 residues) is the two anti-parallel α -
helices that form part of the stem of the molecule. One of the helices is among the longest 
known in globular proteins (75Å). The HA1 and HA2 chains of each monomer are 
connected via a single disulfide bond. The HA2 subunit terminates in an α-helical 
structure near the protease cleavage site. The hemagglutinin trimmer is stabilized from 
interactions between the major HA2 α -helices in the formation of a triple-stranded coiled 
coil in the trimmer’s interior. The N-terminal (top) half of the coiled-coil super helix is 
tightly packed with several nonpolar residues in van der Waals contact around the three-
 11
fold axis. The C-terminus end of the super helix expands away from the axis with polar 
and charged residues from each monomer experiencing electrostatic repulsion from like 
residues in the other monomers 
The influenza virus binds to the cell surface by fixing the outer top of the HA to 
the sialic acid of a cell’s glycoproteins and glycolipids. The sialic acid linkage to the 
penultimate galactose, either α 2→3 (in birds) or α 2→6 (in humans), determines host 
specificity 33, 36-38. Avian influenza viruses generally show the highest affinities for α 
2→3 linked sialic acid.  In birds targeted by these viruses, α 2→3 linked sialic acid is the 
dominating receptor type in epithelial tissues of endodermic origin (gut, lung).  In 
contrast, human-adapted influenza viruses, primarily access α 2→6 linked residues which 
predominate on non-ciliated epithelial cells of the human airway. The different receptor 
preferences help in preventing hassle-free transmission of avian viruses to humans thus 
creating a species barrier 39.  However, recently, it was shown that there is a population of 
ciliated epithelial cells in the human trachea, which also carry avian receptor-like glyco-
conjugates at lower densities 40, 41. Also chicken cells carry human-type sialic receptors at 
low concentrations. In pigs and quails, both receptor types are present at higher densities, 
thus making these species great hosts for mixing avian and human strains 42. 
After attachment, the cell via a clathrin-coated pit receptor-mediated endocytosis 
process, as shown in Figure 6, takes up the virus
. 
The time from entry to production of 
new virus is on average six hours 12 
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Figure 6: Replication cycle of influenza A virus. Binding and entry of the virus, fusion with endosomal 
membrane and release of viral RNA, replication within the nucleus, synthesis of structural and enveloped 
proteins, budding and release of virions capable of infecting neighboring epithelial cell 43. 
 
 
1.1.4 Neutralization of Infectivity by Antibodies  
Since viral attachment to cells is the first step in the infectious cycle, its inhibition 
would appear to be an effective way of preventing infection. HA contains the receptor 
binding site and studies have shown that anti-hemagglutinin antibodies neutralize virus 
infectivity in vitro, in addition to providing protection against infection 44. A direct 
correlation between inhibition of virus binding to cells and neutralization of infectivity 
has been shown 45. There are however, uncertainties about the mechanism of 
neutralization of influenza virus. Knoswo et al determined the structures of HA-AB 
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complexes with three distinct antibodies and was able to provide more insight on the 
mechanism by which anti HA antibodies neutralize infectivity 44. The epitopes 
recognized by three antibody studies were located on the receptor-binding domain. Two 
of them overlapped with the receptor-binding domain and blocked access to it while the 
third had the ability to prevent the structural transition of HA that is required for fusion of 
virus and cellular membranes 46-48. These three antibodies are thought to be representative 
of the range of neutralizing antibodies that react with HA. 
The fact that the affinities of antibodies for HA are much stronger than the 
affinities of the receptor-binding site for sialic receptor analogues, allows antibodies to 
effectively block receptor binding. Comparison of the sizes of the receptor-binding site 
(800 Å2) 33 , and of antibody–antigen interfaces of the  monoclonal antibodies  that 
contact amino acid residues that are components of the receptor-binding site, indicates 
that ‘antibody footprints’ (1200 and 1500 Å2 ) 20, 49 are larger. Therefore, in addition to 
covering the receptor-binding site, the antibody would also cover HA residues that are 
not involved in binding to receptor. Mutations at these positions are what allow virus to 
escape neutralization without imposing selective pressure on residues of the receptor-
binding site that could compromise its activity. Support for these conclusions is provided 
by the findings that the receptor-binding site is formed by conserved residues and that all 
the mutations which allow the virus to escape neutralization by antibodies that partially 
overlap the receptor-binding site, are at positions outside the site 48.  
The relationship between antigenicity and immunogenicity remains unclear as our 
knowledge of the determinants of HA immunogenicity and of other factors that lead to 
the induction of antibodies with varying ranges of specificity in different infected 
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members of the population, is incomplete. It is nevertheless essential for an 
understanding of the pathway of antigenic drift and possibly also for attempts at effective 
vaccination of all sections of the population. Among the initial steps towards 
understanding antigenicity, is the comparison of antibody binding specificity towards 
different mutated HAs. The purpose of this study was to collect information regarding the 
change in binding specificity of HA to a specific antibody due to antigenic mutation of 
HA. Such information might enable prediction of subsequent structural and antigenic 
changes, as no identification of mutation preference or the ability to predict changes has 
been achieved.  As a complementary approach to in vitro experiments (e.g. isothermal 
titration chemistry), molecular dynamics (MD) simulations could provide such 
information. 
 
1.2 Computer Molecular Modeling 
1.2.1 Molecular Modeling 
Molecular modeling is a multidisciplinary field that encompasses laws and 
theories that stem from mathematics, physics, chemistry and biology and employs 
algorithms from computer science and information theory. It can be defined as the art and 
science of studying molecular structure and function through theoretical and 
computational techniques by building models or mimicking the behavior of molecules.   
The role of computation in biology and biological chemistry has shown a steady 
increase over the past decades due to continued growth of computing power, in particular 
in the context of personal computers. Simulations that were difficult for yesterday’s super 
computers can be carried out today using standard office workstations. Use of parallel 
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computers, which couple processors together in such a way that calculation is divided 
into small pieces with results being combined at the end, has also enhanced the ability to 
analyze, compare, and characterize large and complex data sets that are obtained from 
experiments on bimolecular systems.  
 In addition, the ability of computer simulations to complement experiments by 
providing averages and confirming distributions or interactions between parts of the 
system for a variety of properties of bimolecular systems that cannot be measured by 
experimental means, have rendered the method invaluable.  
As a counterpart to experiments, Molecular Dynamic (MD) simulations are used 
to estimate equilibrium constants and dynamic properties of complex systems that cannot 
be calculated analytically. Modeling approaches thus symbolize the exciting interface 
between theory and experiment by filling in the many gaps, thus enabling building of 
better models and theories that ultimately make (testable) predictions 50, 51. 
Molecular modeling studies usually involve three stages. In the initial stage, a 
model is selected to describe the intra and inter-molecular interactions in the system. The 
two most commonly used models are quantum mechanics and molecular mechanics; both 
enable the energy of any arrangement of atoms and molecules in the system to be 
calculated. They also allow the determination of energy variation in the system as 
positions of atoms and molecules change. The second stage is the calculation itself. 
Calculations such as energy minimizations, molecular dynamics and Monte Carlo 
simulation/conformation can be made. The last stage involves analysis of the calculation; 
to not only calculate properties, but to check that it was performed properly. 
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1.2.2 Biomolecular Force Fields (Molecular Mechanics) 
The potential energy of intramolecular and intermolecular interactions is one of 
the most important variables in computer modeling. Molecular mechanics is based upon a 
rather simple model of these interactions within a system in addition to contributions 
from stretching of bonds, the opening and closing of angles and rotations about single 
bonds. 
The basic concept is that, given a molecular structure (i.e., cartesian or internal 
coordinates for all the atoms), we can calculate the energy of interaction between all 
atoms. In this way, the energy values of the molecular conformations found in nature can 
be calculated. The intermolecular energy between two molecules interacting such as a 
drug molecule interacting with proteins or two proteins interacting with each other can 
also be calculated. The molecular potential energy is presumed to be a sum of energy 
terms that correspond to physical effects such as electrostatic interactions, dispersion and 
repulsion energies, bond distance and bond angle distortion. The energy is assumed to be 
a function of the number and type of chemical species within the molecule and the 
distance between all pairs of atoms (see equations below).  
E = Ebonds + Eangle + Edihedral + Enon − bonded 
Enon − bonded = Eelectrostatic + Evan der Waals 
The set of parameters consisting of equilibrium bond lengths, bond angles, partial 
charge values, force constants and van der Waals parameters are collectively known as 
force fields and can be better described as the functional form and parameter sets used to 
denote the potential energy of a system of particles. Different implementations of 
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molecular mechanics use slightly different mathematical expressions, thus different 
constants for the potential functions. It should be noted that transferability is a key 
attribute of a force field, as it enables a set of parameters developed and tested on a 
relatively small number of cases to be applied to a much wider range of molecules.  
The common force fields in use today were developed by using high-level 
quantum calculations and/or fitting experimental data. Only if constructed and 
parameterized correctly will the energy models generate reliable structural predictions. 
There are a number of complete sets of energy parameters available, which describe 
different interactions between, for example, all atoms in a protein or nucleotide. These 
force fields have their roots on the pioneering work of Momany et al. 52, 53 and 
Lifson/Hageler et al. 54. Momany and his coworkers developed the Emperical 
Comformational Energy program for Peptides Potential (ECEPP) by starting from 
accurate geometric data for all amino acids while keeping bond lengths and bond angles 
fixed and terms optimized to crystal packing data, while, Lifson and Hagler developed an 
empirical data set for amides and carboxylic acids  where a limited set of parameters 
(including partial charges, but without special hydrogen parameters) was determined by 
least squares fitting to crystal structures, lattice energies and a few dipole moments. 
 The force field used in this study is AMBER 55, an acronym for Assisted Model 
Building and Energy Refinement. It is a family of force fields for molecular dynamics of 
biomolecules originally developed by the Peter Kollman’s group at the University of 
California, San Francisco and also refers to the molecular dynamics simulation package 
that implements these force fields.  
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The functional form of the AMBER force field 56 is:  
V (rN)=Vbonded + Vnonb 
Vbonded =∑bonds Kb (d-do) + ∑angles Ka (θ- θo) +1/2 ∑dihedrals Kd (1+cos (mΦ –γ) 
Vnonb =∑nonbo (A/r12 –B/r6 + qiqj/4Πε0 rij ) 
V denotes the potential energy, which is a function of the positions (r) of N 
particles (usually atoms).  The various contributions are schematically represented in 
Figure 7.  
The first term in the equation, ∑bonds Kb (d-do), represents the energy between 
covalently bonded atoms. The two parameters that define the bond are the force constants 
Kb and do. The interactions between a pair of bonded atoms is modeled by a harmonic 
potential that gives the increase in energy as the bond length d deviates from the 
reference, do. The force is a good approximation near the equilibrium bond length, but 
becomes increasingly poor as atoms separate.  
The second term ∑angles Ka (θ- θo) is an energy summation over all valence angles 
in a molecule and is again modeled using a harmonic potential and requires two 
parameters; Ka is a force constant and is an ideal bond angle while θo depends primarily 
on the hybridization of the central atom in the angle. 
The third term 1/2 ∑dihedrals Kd (1+cos (mΦ –γ) ,  represents the energy of twisting 
a bond due to bond order ( single or double bonds) and neighboring bond or lone pairs of 
electrons. It is a torsional potential and models how the energy changes as the functional 
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groups at either end of a bond rotate relative to each other. Each dihedral in the molecule 
requires three parameters to calculate the energy of the angle, a rotational barrier (Kd), 
number of local minima(m), and the value of the dihedral angle at which the energy is a 
minimum (related to γ). 
The fourth and last contribution ∑nonbo (A/r12 –B/r6 + qiqj/4Πε0 rij) is the non- 
bonded term.  It represents the non-bonded energy between all atom pairs that are in 
different molecules or that are in the same molecule but are separated by at least three 
bonds. The non bonded term can be decomposed into van der Waals interactions, 
modeled by using Lennard-Jones potential 57 and electrostatic energies, modeled using a 
Coulomb potential 58, 59 term where r is the inter-atomic distance between two ions, qi  
and q2 the electric charges in coulombs carried by atoms 1 and 2 respectively, and ε0 is 
the electrical permittivity of space. The electrostatic interaction is neglected for atoms 
sharing a common bond or bond angle. The parameter A accounts for intermolecular 
repulsion at short distances. The parameter B accounts for attractive dispersion forces.  
Figure 7:  Schematic 
representation of the 
four key contributions 
to a molecular 
mechanics force field; 
bond stretching, angle 
bending, torsional terms 
and non-bonded 
interactions. 
 
  
1.2.3 Molecular Dynamics Simulation  
The MD approach is simple in principle. A system is stimulated in motion by 
following molecular configurations in time according to Newton’s equation of motion 
(F=ma) under the influence of a specified force field (which as stated earlier is essentially 
the mechanical representation of the system and assumes simple, pair wise –additive 
potentials for the system, that expresses how the composite atoms stretch, vibrate, and 
rotate about the bonds in response to intramolecular and intermolecular forces). The 
result is a trajectory that specifies how the positions and velocities of the particles in the 
system vary with time.  
A MD trajectory consists of three essential parts: initialization, equilibration, and 
production.  An initial configuration of the system is first established. An equilibration 
phase is then performed, during which the system evolves from the initial configuration. 
Thermodynamic and structural properties are monitored during the equilibration until 
stability is achieved. At the end of the equilibration, the production phase commences. It 
is during the production phase that simple properties (e.g. energy, temperature, pressure 
and density) of the system are calculated. At regular intervals, the configuration of the 
system is outputted to a disk file. Finally the simulation is analyzed; properties not 
calculated during the simulation are determined and the configuration examined both to 
discover how the structure of the system changed and check for any unusual behavior that 
might indicate a problem with the simulation. 
 The first stage, initialization, involves specifying the initial coordinates and 
velocities for the solute macromolecule and for the solvent and ion atom. The initial 
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coordinates are either available from experiment (e.g. crystal structures) or can be 
acquired through homology modeling.  Not surprisingly, the starting coordinates 
collected from experiment and homology modeling generally does not correspond to a 
minimum in potential energy. This is due to methods used to obtain crystal structures 
neglecting effect of solution to structure, thus not encouraging stable states of molecular 
system that correspond to local minimum energy. In addition, choice of force field used 
to represent crystal structure also affects net potential energy. Minimization (further 
refinement) is therefore usually done to relax strained contacts. First order minimization 
algorithm (energy minimization techniques) that are frequently used in molecular 
modeling to minimize the potential energy include steepest descent and conjugate 
gradient minimization techniques 60. These gradually change the coordinates of the atoms 
as they move the system closer and closer to a minimum energy. The starting point for 
each iteration is the molecular configuration obtained from the previous step.
 
For the first 
iteration, the starting point is the initial configuration of the system provided by the user.
   
Energy minimizations generate individual minimum energy configurations of a system. 
In some cases, the information provided by energy minimization can be sufficient to 
predict accurately the properties of a system.  However, this is possible only for relatively 
small molecules of small molecular assemblies in the gas phase where minimum 
configurations on energy can be identified and statistical mechanical formulae can be 
used to derive a partition function from which thermodynamic properties can be 
calculated.  To study more complex systems (like the current HA-AB system), energy 
minimization techniques prepare the system for other types of calculations (like 
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molecular dynamics) by relieving any unfavorable interactions in the initial configuration 
of the system.  
Many simulations of macromolecules were initially simulated in vacuo due to 
computer limitation, but with the realization that most macromolecules are naturally 
hydrated and hydration plays a big role of how they function, there was a need to come 
up with a way to get the correct balance between water and water solute interaction in the 
calculation. This problem was solved with the increase in the power of modern 
computers, which has allowed inclusion of explicit solvent (water molecules and counter 
ions) around the protein. Choosing the best water model has been a major interest of 
research in itself because of the problem of finding a model that can represent the 
anomalous properties of water in solid, liquid and gas phases. The current commonly 
used models are the SPC mode 61 and TIP3P and TIP4P model 62. In TIP3P model (used 
in this study), three sites are used for the electrostatic interactions; the partial positive 
charges are partially balanced by an appropriate negative charge located on the oxygen 
atom. The van der Waals interaction between two water molecules is computed using a 
Lennard-Jones function 57 with just a single interaction point per molecule centered on 
the oxygen atom; no van der Waals interactions involving the hydrogen atoms are 
calculated.  
 
Figure 8: TIP3P water model. It contains three 
simple interaction sites corresponding to the three 
atoms of the water molecule. Each atom gets 
assigned a point charge, and the oxygen atom also 
gets the Lennard-Jones parameters. 
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If crystallographic data is used, before continuing with the molecular dynamics, 
other factors need to be considered in the initial stages. For example, since the three-
dimensional structures of biological macromolecules are stabilized by the presence of 
hydrogen bonds between secondary structural elements in proteins and between the bases 
in DNA and these are usually not included in crystallographic data, they need to be added 
in order to do a more accurate simulation. In addition, even though the coordinates of 
some of the solvent molecules may be known, it is necessary to add other solvent 
molecules to give the appropriate solvent density. This is usually done using the LEaP 
program in AMBER or other online programs, for example H++ 63-65. 
Design of molecular dynamics simulations should also take into account available 
computational power. Simulation size (number of particles), time step and total time 
duration must be selected so that the calculation can be completed within a reasonable 
time period, but long enough to be relevant to the time scales of the natural process being 
studied.  The spanning times related to protein dynamics most commonly indicated in 
literature vary between several nanoseconds to several microseconds, which take several 
CPU days or years.  Parallel algorithms are sometimes used that allow the load to be 
distributed between CPU’s. Computational costs can also be reduced by employing 
electrostatic methods such as the particle mesh Ewald 66, good spherical cut off 
techniques or using algorithms such as SHAKE 67, which fix the vibrations of the fastest 
atoms (e.g. hydrogen) into place. When a cut off is employed, the interactions between all 
pairs of atoms that are further apart than the cut off value are set to zero. 
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 After doing the MD simulation, there are various different computational 
techniques available for use depending on properties to be studied to further predict the 
properties of a system like structure prediction, conformational analysis, sequence 
analysis, protein folding, solvation energies, and free energies.  
 
1.2.4 Free Energy Calculations 
The free energy is often considered the most important quantity in 
thermodynamics. The free energy is usually expressed as the Helmholtz function, A (used 
for a system with a constant number of particles, temperature and volume – constant 
NVT) 68 or the Gibbs function, G ( used for a system with constant number of particles, 
temperature and pressure - constant NPT ) 69.  Most experiments are conducted under 
conditions of constant temperature and pressure, where the Gibbs function is the 
appropriate free energy quantity.  
 Various techniques have been used to predict relative binding free energies of 
protein-protein association 70-73. The Molecular Mechanics Poisson Boltzmann/ 
Generalized Born surface area (MM-PB(GB)SA) 74, 75 method was chosen for this study 
as other methods were not considered conducive as they suffer from long computational 
times in addition to potential technical difficulties associated with creation and 
annihilation of atoms. The MM–PB(GB)SA method is a recently introduced approach to 
predict free binding energies of a complex of molecules in solution. The method has been 
applied successfully to study protein-peptide, protein-protein, protein ligand, protein 
nucleic acid, nucleic acid-ligand interactions, processes such as protein folding, and the 
conformation- dependent free energies of nucleic acid. More specifically, the method has 
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been used to predict, the relative stabilities of A-DNA and B-DNA, effects of alanine 
mutations on protein-protein interactions 76, and binding of steroids to anti-progesterone 
and anti-testosterone antibodies 77.  
MM-PB(GB)SA approximates free energies using a Poisson-Boltzmann (PB) 
continuum or generalized Born (GB) representation of the solvent together with a surface 
area-dependent term and molecular mechanics energies using snapshots from MD or 
Monte Carlo methods (not discussed) simulations generated with continuum solvent 
approaches. All snap shots collected are stored in AMBER format and the molecular 
energies are determined with the anal program from AMBER, representing internal 
energy (bond, angle and dihedral) and van der Waals electrostatic interactions.  
Free energy calculations performed by using the MM-PB(GB)SA approach are 
described by Srinivasan et. al 78 and discussed in more detail in the method section. To 
use the MM-PB (GB)SA method, the user has to supply:  
1) Trajectory files from MD 
2) The input files for the anal program  
3) The topology files for all interacting molecules without waters or their mutants, 
depending on the purpose of the run 
4) The files with the charge and van der Waals parameters 
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1.3 Research Question/Hypothesis  
As stated earlier, the inhibition of binding of the influenza HA to the sialic cell 
receptor is an effective way of preventing infection as it contains a sialic acid cell 
receptor-binding site. Mutations at these positions causes reduction in antibody affinity, 
allowing viruses to escape from neutralization without imposing selective pressure on 
residues of the receptor-binding site that could compromise its activity. As a 
complementary approach to experiments, molecular modeling and molecular dynamics 
simulations using the AMBER force field and MM-PB(GB)SA free energy calculation 
method are used to collect information regarding the trend and effect of single and 
multiple mutations of HA to antibody binding specificity of seven different isolates of the 
influenza virus over a range of 20 years. Virus strains from later years were expected to 
have similar or increased affinity to earlier virus-specific antibodies when they no longer 
posed a primary threat to the virus survival.  
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METHODS  
 
 
 
 
2.1 System set up for MD simulation  
 
2.1.1 Sequence and Data Base Searches and Model Setup 
The original influenza isolate chosen to be studied was based on the availability 
of a previously published paper46 that described an X-ray crystallographic structure of an 
HA-AB complex. From a search of the Protein Data Bank (PDB) data base, initial atomic 
coordinates for the antibody complex were obtained from the X-ray crystal structure of a 
recombinant influenza strain containing A/Aichi/68 (H3N2) HA complexed with the Fab 
fragment of the anti-influenza neutralizing antibody (PDB ID 1EO8) by Fleury et al., 
determined to 2.8 Å resolution 46, 79. No crystallographic waters were present in this 
crystal structure  
The Influenza Virus Resource website 80 was used to search for sequences from 
the NCBI Influenza Database of other Hong Kong H3N2 virus isolates. A phylogenetic 
dendrogram was then built to enable the selection of influenza viruses with the least 
similarity and most differences between the sequences. Six influenza viruses were 
selected: A/Hong Kong/l/68 (H3N2), A/Hong Kong/l/69 (H3N2), A/Hong Kong/l/74 
(H3N2), A/Hong Kong/l/75 (H3N2), A/Hong Kong/l/85 (H3N2), A/Hong Kong/l/92 
(H3N2) and A/Hong Kong/l/99 (H3N2). 
To construct the three-dimensional models of the six HAs, a multiple sequence 
alignment of the viruses versus the A/Aichi/68 influenza HA of known structure was 
done using NCBI -BLASTP 2.2.20+ 81 so as to find areas where mutations had taken 
place.  BLAST (Basic Local Alignment Search Tool) is an online program that finds 
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regions of local similarity between sequences, by comparing nucleotide or protein 
sequences to sequence databases and calculating the statistical significance of matches. 
All the HAs and their complexes were then constructed using Swiss-PdbViewer (Swiss-
Pdb Viewer, also known as deep view, is an application that provides a user friendly 
interface that allows analysis and modeling of several proteins at the same time 82) and 
RasMol (molecular visualization software 83), from the initial coordinates of the 
A/Aichi/68 (H3N2) HA–AB crystal structure. Amino acids were added, deleted or 
replaced with residues manually to create mutated proteins. It was discovered that the 
original PDB had some errors in residue numbering in the antibody (number 32 was 
missing). A program was created by A. Poe (NMU Computer Science Department) to 
correct this so that the numbering for all the atoms was consistent. 
 
2.1.2 Structure Refinement  
A preliminary pKa calculation was performed for all the starting structures of HA 
and their complexes using the WebServer H++ 63, 65, which is an automated system that 
computes pK values of ionizable groups in macromolecules and adds missing hydrogen 
atoms according to the specified pH of the environment. The PDB files generated by the 
H++ program were further edited after they were generated so that the LEaP program of 
AMBER could correctly read them. Some of the changes that had to be made manually in 
the PDB files included altering three letter abbreviations of Histidine, Lysine and 
Cysteine. Histidine can exist either as the protonated species or as a neutral species with a 
hydrogen at the delta or epsilon position. For this reason, the Histidine unit/residue name 
is either HIP, HID, or HIE (but not HIS). The AMBER force fields also differentiate 
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between the residue Cysteine (CYS) and similar residues that participates in disulfide 
bridges, Cystine (CYX), substituting CYX for CYS in the sequence was thus done to 
ensure correct disulfide bond creation. Aspartic acid--protonated ASH, Cystine, S--S 
crosslink CYX, Histidine, delta H HID, Histidine, epsilon H HIE, Histidine, protonated 
HIP. A general rule of thumb that was followed was to keep editing the input PDB file 
until LEaP stopped reporting errors for all the structures. 
Sodium ions/Chloride counter ions were then added to the HA-AB complex by 
using a coulombic grid potential 59 via the LEaP module of AMBER to maintain the 
system at charge neutrality. The grid potential positions the ions at the most energetically 
favorable position near the protein. The system was then solvated using equilibrated 
TIP3P water in a rectangular periodic box as a building block 62.  The complex had at 
least a 10 Å buffer in every direction of the box to permit substantial fluctuations of the 
conformation during the course of the MD simulation. 
 
2.2 Evaluation by Molecular Dynamics 
To fix any errors introduced in the model-building process, the Sander module in 
the AMBER 7 program package was used to carry out minimization and molecular 
dynamics. The program relaxes the structure by iteratively moving the atoms down the 
energy gradient until a sufficiently low average energy gradient is obtained. 
Non–bond long range interactions were cut off at 12.0 Å and three stages of 
minimizations performed to the water, hydrogens, amino acid side chains, and the entire 
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structure; so as to remove initial steric clashes. The whole system (including protein (HA 
alone or HA-AB complexes), water and hydrogen) was minimized with 200 steps of 
minimizations. The protein atoms were then fixed, to allow only the water to move and 
500 steps of minimization done in a constant volume periodic boundary to relax the 
water. An additional 500 steps of minimization were then done on the whole system. 
After minimization, the system was equilibrated in two stages. The protein 
molecules were first fixed and the water molecules of the solvated systems equilibrated 
using MD, and then the entire system equilibrated. Due to a problem with the AMBER 
program (the program kept shutting down), the first stage of equilibration was skipped on 
the HA-AB complex of 85, 92 and 99. At the beginning of each stage, the temperature of 
the system was increased gradually from 10 K to 300 K with a 5 ps time constant for heat 
bath coupling of the system. The target constant pressure of 1 atm was achieved and 
maintained by isotropic position scaling, a coupling algorithm used in AMBER. A 0.002 
ps time step was used. The Berendsen temperature coupling algorithm 84 was used to 
maintain the system at its assigned temperature (300 K), with a scaling factor time 
constant. All covalent bonds in the protein and in water were represented by constraints 
that kept the bond distances to the proper chemicals values. The SHAKE algorithm 67 
was used to fix the length of  bonds containing a  hydrogen atom to their equilibrium 
values. Constraints were applied to all bonds involving hydrogen atoms of 0.2 Å. The 
particle mesh Ewald 66 method was used to treat long range electrostatic interaction. To 
minimize computational expense, long-ranged non-bonded interactions (van der Waals 
interactions) were calculated out to a 12 Å residue-base cutoff distance. 
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Before proceeding with the production MD run, temperature, density and total 
energy versus time graphs were constructed to verify that the system had equilibrated. 
From the figures, it was clear that the energy, temperature and density had all clearly 
converged by the end of the equilibration period, and thus as a final step to the MD 
simulations, 600 ps production simulation were performed at constant pressure and 
temperature (300 K) after the system was equilibrated. A snapshot of the trajectory was 
stored every ps (500 time steps) for later analysis. To allow for sufficient equilibration, 
only the latter 500-ps of each 600-ps simulation were used for subsequent analysis of the 
dynamics.  
In all calculations, the AMBER 94 force field 55, 56 was used. The MD simulation 
was performed using the AMBER suite of programs, version 7.0 85. Apart from what is 
mentioned above, all other default settings were used in the simulations. Illustrations of 
proteins were generated with the RasMol program 83. The different steps of the 
simulations were performed partly on a parallel 2.8 GHz Pentium IV processor personal 
IBM laptop computer, partly on a 2.2 GHZ Intel core 2 Duo Mac OS X laptop and partly 
on a Beowulf cluster composed of a 32 node dual processor.  
2.3 Energy Analysis: MM–PB (GB) SA Calculations  
The MM-PB(GB)SA 75 method as implemented in AMBER 7 was used to 
calculate the binding energy for non-covalent  association of the influenza viruses and the 
antibody. In the MM-PB(GB)SA method the average binding free energy (∆G
 bind) is 
calculated as shown in Figure 9. 
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Figure 9: The binding free energy (∆Gbind ) as defined by calculation from solute (∆Gsolute ) and 
solvent (∆Gsolvation ) contributions. Total molecular mechanical energy of the solute (∆EMM) 
represents average interaction energies obtained from performing calculations on ensemble of 
uncorrelated snapshots from the equilibration MD; Electrostatic energy calculated from the 
Coulomb potential (∆EELE); van der  Waals distance-dependent interaction energy calculated from 
the Lennard-Jones potential (∆EVDW); Internal energy from bonds, angles and torsions  (∆EINT ,); 
Electrostatic solvation contribution from solving  the Generalized  Born equation (∆GGB) or 
Poisson Boltzmann equation (∆GPB) of MM (GB/PBSA) in  Amber 7; ∆GSA is an empirical term 
for the non-electrostatic contribution. γ is a surface tension parameter, and was set to 0.00542 
00542 kcal mol-1  A-2 for PB and 0072 kcal mol-1  A-2 for GB ;  SASA is the solvent-accessible 
surface area determined by Sander’s LCPO method  in  Amber and β is a parameterized value, set 
to 0.92 kcal mol-1 for PB and 0 for GB.  
 
As shown in Figure 9, the free energy of any binding process may be divided into 
a contribution from the solute and a contribution from the solvent:  
G (X) = Gsolute (X) + Gsolvation (X)  
The free energy contribution from the solvent and dissolved ions is calculated by 
solving the linearized PB or GB equation for each of the three states, unbound 
components and complex (gives the electrostatic contribution to the solvation free 
energy) and adding an empirical term for the non electrostatic contribution, calculated 
from the solvent–accessible surface area (SASA). This may be expressed as follows:  
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∆Gsolvation (X) =∆GGB (X)+ ∆GSA (X)  
∆GGB  is the electrostatic contribution, obtained from PB or GB method.  
∆GSA (X) is the non-electrostatic contribution calculated by  
∆GSA (X) = γ (∆SASA) + β  
 γ  is a surface tension parameter, and  was set to 0.00542 kcal mol-1 Å -2 for PB and 
0.0072 kcal mol-1 Å -2 for GB.  SASA (X) is the solvent-accessible surface area of 
molecule X, determined by Sander’s (Simulated annealing with NMR-derived energy 
restraints. This allows for NMR refinement based on NOE-derived distance restraints, 
torsion angle restraints, and penalty functions based on chemical shifts and NOESY 
volumes) Linear Combinations of Pairwise Overlaps (LCPO) method 86.  In this 
experiment β is a parameterized value, set to 0.92 kcal mol-1 for PB and 0 for GB. 
Calculating the average interaction energy between the receptor and the ligand 
and taking the entropy change upon binding into account, if necessary, is how the free 
energy contribution from the solute is obtained. This may be expressed as follows 
∆Gsolute =∆EMM - T∆S 
∆EMM = ∆EELE + ∆EVDW + ∆EINT 
∆EMM represents the average interaction energies obtained from performing 
calculations on an ensemble of uncorrelated snapshots collected from an equilibrated 
molecular dynamics (MD) simulation where ∆EELE is the electrostatic energy calculated 
from the Coulomb potential; ∆EVDW  is the van der  Waals distance-dependent interaction 
energy calculated from the Lennard-Jones potential; ∆EINT  is the internal energy due to 
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bonds, angles and torsions. The entropy contribution (∆S) can be found by performing 
normal mode analysis on the three species. However, entropy contributions are neglected 
in this case as normal mode analysis calculations are computationally expensive and tend 
to have a large margin of error that introduces significant uncertainty in the result. 
Neglecting entropy contributions has been found to still produce fairly accurate results 
when only a comparison of states of similar entropy is desired such as two ligands 
binding to the same protein 74.  
In principle, the calculation of the binding free energy described above would 
require three independent MD simulations of the complex and both individual protein 
(HA and antibody). This protocol is referred to as “separate trajectories” or “ three 
trajectories” (3T) by Gohlke and Case 74. However an assumption was made that no 
significant conformational changes occur upon binding i.e. structural adaptation is 
negligible and the snap shots for all three species can be obtained from the single 
trajectory carried out on the complex by separating the complex into its constituent parts 
(Single Trajectory approach). 
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2.3.1 Generate Snapshots  
To extract snapshots (without the water) from production runs for use in the MM-
PBSA 75 calculation, the mm_pbsa.pl script (provided in AMBER 7), that automates this 
extraction process was used.  Snapshots were generated for the complex as well as the 
receptor by itself and the ligand by itself from the MD trajectory file for subsequent MM-
PB(GB)SA analysis.  The input file used was the mm-pbsa.in (provided in AMBER 7). 
This input file specifies which atoms are part of the receptor, ligand and complex as well 
as specifying the total number of snapshots in the trajectories, the stride length, the names 
of the trajectory files and the prmtop files corresponding to the unsolvated structures. 
Prmtop files are topology files of the proteins that were created using LEaP after 
stripping water from solvated PDB files. After executing the mm_pbsa.pl command, 
approximately sixty equally spaced snapshots files were generated for the complex, 
receptor and ligand, from the trajectory file. As noted above, it is preferable that the 
snapshots are uncorrelated which is more likely if they are separated in time. The amount 
of snapshots (sixty) was selected so as to complete the calculation in an average of three 
days for each complex.  
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2.3.2 MM-PB(GB)SA Binding Energy Calculation 
Starting with the snapshots extracted, the interaction energy and solvation free 
energy for complex, receptor and ligand were calculated and results averaged to obtain an 
estimate of the binding free energy. The binding energy calculation for the process                         
A + B   AB  i.e. the association of  HA with AB to form the HA-AB complex was done 
using both the MM-PBSA method and the MM-GBSA method for comparison. This was 
accomplished by editing the input file for mm_pbsa.pl. Various portions of the input file 
specify which calculations to run, on which files to run them and any special parameters 
necessary to calculate the different contributions to the binding free energy. The ligand, 
receptor, and complex were all turned on (specified to be included in calculations), and 
the terms MM (Molecular Mechanics), GB, PB and MS(Molsurf) were computed for 
each species (see below). 
MM - Calculation of gas-phase energies using Sander  
GB  - Calculation of solvation free energies using the GB models in Sander  
PB  - Calculation of solvation free energies using Delphi (The PB method called by the 
MM-PBSA, is implemented in the program Delphi). The Delphi program is not 
distributed with AMBER and therefore was installed locally 87-90. 
MS - Calculation of nonpolar contributions to solvation using Molsurf. MolSurf is a 
program for the generation of molecular properties. MS = 0, in this study, so nonpolar 
contributions were instead calculated with the LCPO method in Sander. 
When finished, as expected, five output files were produced: binding_energy.log, 
snapshot_statistics.out, snapshot_com.all.out, snapshot_rec.all.out, snapshot_lig.all.out. 
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The all.out files gave the individual energy contributions for each of the snapshots for 
each of the proteins  (for the HA, antibody and complex, respectively) while the 
statistics.out file contains the energy components for complex, HA and antibody 
separately and the final averaged binding energy (under the category DELTA). A 
calculation of the entropy contribution to binding was not done, so strictly speaking the 
results of this study was not a true free energy value but could be used to compare similar 
systems. The log file just indicated the success of the completed calculation. 
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RESULTS  
 
 
 
 
Six mutated influenza HAs and their antibody complexes were successfully 
constructed and their change in binding energies calculated using the MM-PB(GB)SA 
method. The six, A/Hong Kong H3N2 strains chosen were from 1969, 1974, 1975, 1985, 
1992, and 1999. They were selected to give the widest possible spread of variant types as 
shown by their dissimilarity to the original A/Hong Kong/l/68 (H3N2)-PDB (1EO8). This 
was based on a Hong Kong influenza phylogenetic tree (Figure 10) that demonstrated 
lack of similarity between the chosen influenza strains: A/Hong Kong/l/68 (H3N2), 
A/Hong Kong/l/69 (H3N2), A/Hong Kong/l/74 (H3N2), A/Hong Kong/l/75 (H3N2), 
A/Hong Kong/l/85 (H3N2), A/Hong Kong/l/92 (H3N2), A/Hong Kong/l/99 (H3N2). The 
1999 HA was the most disimilar to the 1968 HA. Their HA-AB complexes were 
constructed using the 1968 HA X-ray structure as a template. 
 
 
 
Figure 10: Phylogenetic relationship between the seven Hong Kong HAs depicting an evolutionary 
relationship and showing the lack of similarity between the chosen influenza isolates. The distance of one 
group from the other groups indicates the degree of relationship i.e., the most similar sequence pairs 
(Highest % sequence identity) are placed close together in a phylogenetic tree. Dissimilar pairs are placed 
furthest apart. The length of the horizontal lines is proportional to the number of amino acid differences. 
The 1999 HA is the most dissimilar to the 1968 HA. 
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To construct the three-dimensional models of the six HAs, a multiple sequence 
alignment of the HA protein sequences versus the A/Aichi/68 influenza virus of known 
structure was done so as to locate areas where mutations had taken place. The sequence 
alignment generated by NCBI–BLAST 81 is shown below in Figure 11 and the exact 
mutations in Table 1. As expected, high similarity is observed between all the proteins 
with the lowest sequence identity in a pair wise comparison found in antigenic sites of the 
influenza HA proteins 34, 91. 
 Most of the mutations were conservative in terms of polarity (e.g., 147, Asn → 
Ser, both polar amino acids or 137, Ile → Val, both hydrophobic). No conservation trend 
was seen in size of amino acid or acidity (e.g. some amino acids changed from larger to 
smaller one and others from basic to acidic or vice versa). The 1999 HA had the most 
mutations (41 amino acids changed from previous year) followed by 85 HA (23), 92 HA 
(14), 75 HA (10), 74 HA (9). The 1969 HA had the least (three).  
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BLASTP 2.2.20+ RID: ZH0AE4G011N Query= gi|324132|gb|AAA43178.1| hemagglutinin 
precursor [Influenza A virus (A/Aichi/2/1968(H3N2))] Length=566  
ALIGNMENTS 
Query     1    MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ  60 
ABB80034  1    .............V..............................................  60 
ABB04294  1    .............V................................N.............  60 
ABB04928  1    .............VFA..............................N.............  60 
ABB04349  1    .............VFA.K............................N.............  60 
ABB04906  1    ..........L..VFA.K............................N.............  60 
CAC40044  1    ............MV.......KG.N........................V..........  60 
Query     61   SSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPD  120 
ABB80034  61   .................L..........................................  120 
ABB04294  61   ..................N..............G....K.....................  120 
ABB04928  61   ..................N..............G....K.....................  120 
ABB04349  61   .....R..DS.......KN..............G....K.....................  120 
ABB04906  61   .....R..DS.......KN..............G...KE..........Y..........  120 
CAC40044  61   NL.M....S........AN..............G....K....I...............E  120 
Query     121  YASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVL  180 
ABB80034  121  ............................................................  180 
ABB04294  121  .................N...N.................D..........Y.........  180 
ABB04928  121  .................N...N.I..............TD..........Y........Q  180 
ABB04349  121  .................N...N......S...Y.....SVNS........Y..E.K....  180 
ABB04906  121  .................N.D.N....A...D.Y.....SVKS........H..EYK..A.  180 
CAC40044  121  H......I........VN.S.N.................D.S........Y...N...M.  180 
Query     181  NVTMPNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVR  240 
ABB80034  181  .................V..........................................  240 
ABB04294  181  .................V.....D....N.............K.................  240 
ABB04928  181  .........S.......V.....DK...D.......K.....K.........V.......  240 
ABB04349  181  .......GK........V.....DK...N...R...K.....K.....V...........  240 
ABB04906  181  ........K........V.....DR......IR...K.....K.....V...........  240 
CAC40044  181  ......S.G........V.....DR..IN.......KI....K.........V.......  240 
Query     241  GLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITP  300 
ABB80034  241  ................................................T...........  300 
ABB04294  241  .................I................................G.........  300 
ABB04928  241  .................I................................G..S......  300 
ABB04349  241  .................I.L...T...........I..............G..N......  300 
ABB04906  241  .................I.L...T...........I..............G..S......  300 
CAC40044  241  .................I.I.S.............VH.............E..S......  300 
Query     301  NGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWE  360 
ABB80034  301  ............................................................  360 
ABB04294  301  ..............................................I.............  360 
ABB04928  301  ..............................................I.............  360 
ABB04349  301  ......................R.......................I.............  360 
ABB04906  301  ..............R.......R.......................I.............  360 
CAC40044  301  ......................................I.......I.............  360 
Query     361  GMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEG  420 
ABB80034  361  ............................................................  420 
ABB04294  361  ............................................................  420 
ABB04928  361  ............................................................  420 
ABB04349  361  ..V....................................L....................  420 
ABB04906  361  ..V....................................L....................  420 
CAC40044  361  ..V...........................N.............................  420 
Query     421  RIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEEMGN  480 
ABB80034  421  ........................................................D...  480 
ABB04294  421  ........................................................D...  480 
ABB04928  421  ........................................................D...  480 
ABB04349  421  ................................................K.......D...  480 
ABB04906  421  ................................................K.......D...  480 
CAC40044  421  ................................................K.......D...  480 
Query     481  GCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISC  540 
ABB80034  481  ............................................................  540 
ABB04294  481  ..............G.............................................  540 
ABB04928  481  ..............G.............................................  540 
ABB04349  481  ..............G.............................................  540 
ABB04906  481  ..............G.............................................  540 
CAC40044  481  ..L........S..D.........NE.............S....T...............  540 
Query     541  FLLCVVLLGFIMWACQRGNIRCNICI  566 
ABB80034  541  ..........................  566 
ABB04294  541  ................K.........  566 
ABB04928  541  ................K.........  566 
ABB04349  541  ................K.........  566 
ABB04906  541  ................K.........  566 
CAC40044  541  ......W.........K........   565 
 
 
 
 
 
 
Figure 11: The sequence 
alignment results of the six 
influenza HA viruses;  
1969 HA  (ABB80034), 1974 
HA (ABB04294), 1985 HA 
(ABB04928), 1992 HA 
(ABB04349), and 1999 HA 
(ABB04906, CAC40044) with 
A/Aichi/68 (AAA43178) as 
generated by BLASTP 2.2.20+. 
Pink highlighted residues are 
the antigenic sites described by 
Wiley et. al 1. 
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Table 1: Color-coded table showing types of mutations. Yellow represents first time an amino acid mutates; 
green, amino acid mutated/reverts back to the original amino acid; orange, second mutation; red, third 
mutation from original; blue, amino acid mutates back to second mutation amino acid. The red number in 
brackets indicates number of amino acid changes in that year, when compared to previous year on table. 
COLOR CODED TABLE SHOWING TYPE AND NUMBER OF AMINO ACID 
MUTATIONS IN EACH HAEMAGLUTININ 
 68 69 74 75 85 92 99   68 69 74 75 85 92 99 
  (3) (9) (10) (23) (14) (41)          
13 Leu Leu Leu Leu Leu Leu Met  162 Gly Gly Gly Gly Ser Ser Ser 
14 Ala Val Val Val Val Val Val  171 Thr Thr Tyr Tyr Tyr His Tyr 
15 Leu Leu Leu Phe Phe Phe Leu  175 Ser Ser Ser Ser Ser Tyr Asn 
16 Gly Gly Gly Ala Ala Ala Gly  176 Thr Thr Thr Thr Lys Lys Thr 
18 Asp Asp Asp Asp Lys Lys Asp  179 Val Val Val Val Val Ala Met 
22 Asn Asn Asn Asn Asn Asn Lys  180 Leu Leu Leu Gln Leu Leu Leu 
23 Asp Asp Asp Asp Asp Asp Gly  187 Asn Asn Asn Asn Asn Asn Ser 
24 Asn Asn Asn Asn Asn Asn Asn  188 Asp Asp Asp Asp Gly Asp Asp 
25 Ser Ser Ser Ser Ser Ser Asn  189 Asn Asn Asn Asn Lys Lys Gly 
70 Asn Asn Asn Asn Ser Ser Asn  190 Phe Phe Phe Ser Phe Phe Phe 
78 Ile Leu Ile Ile Lys Lys Ala  209 Ser Ser Asn Asp Asn Ser Asn 
94 Val Val Gly Gly Gly Gly Gly  213 Gln Gln Gln Gln Arg Arg Gln 
98 Glu Glu Glu Glu Glu Lys Glu  217 Arg Arg Arg Lys Lys Lys Lys 
99 Thr Thr Lys Lys Lys Glu Lys  218 Val Val Val Val Val Val Ile 
104 Val Val Val Val Val Val Ile  223 Arg Arg Lys Lys Lys Lys Lys 
110 Phe Phe Phe Phe Phe Tyr Phe  229 Ile Ile Ile Ile Val Val Ile 
121 Tyr Tyr Tyr Tyr Tyr Tyr His  264 Asn Asn Asn Asn Thr Thr Asn 
137 Ile Ile Ile Ile Ile Ile Val  276 Met Met Met Met Ile Ile Val 
138 Thr Thr Asn Asn Asn Asn Asn  277 Arg Arg Arg Arg Arg Arg His 
140 Gly Gly Gly Gly Gly Asp Ser  289 Pro Thr Pro Pro Pro Pro Pro 
142 Thr Thr Asn Asn Asn Asn Asn  291 Asp Asp Gly Gly Gly Gly Glu 
144 Thr Thr Thr Ile Thr Thr Thr  294 Ile Ile Ile Ser Asn Ser Ser 
147 Thr Thr Thr Thr Thr Ala Thr  492 Ala Ala Ala Ala Ala Ala Ser 
148 Gln Gln Gln Gln Gln Gln Gln  520 Gly Gly Gly Gly Gly Gly Ser 
149 Asn Asn Asn Asn Ser Asn Asn  315 Lys Lys Lys Lys Lys Arg Lys 
153 Asn Asn Asn Asn Tyr Tyr Asn  323 Lys Lys Lys Lys Arg Arg Lys 
159 Pro Pro Pro Thr Ser Ser Pro  324 Tyr Tyr Tyr Tyr Tyr Tyr Tyr 
160 Gly Gly Asp Asp Val Val Asp  363 Ile Ile Ile Ile Val Val Val 
161 Ser Ser Ser Ser Asn Lys Ser  547 Leu Leu Leu Leu Leu Leu Trp 
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  All the HAs and their complexes were constructed using Deep view and RasMol 
from the initial coordinates of the A/Hong Kong/l/68 (H3N2)-PDB (1EO8) crystal 
structure. As can be seen in Figure 12, the vast majority of mutations occur in the distal 
sialic binding domain rather than in the long helical region. It makes sense that the 
mutations would cluster in the antigenic region since changes to the protein structure in 
these regions are likely to allow for escape from antibody. The bottom box in Figure 12 is 
a representation of the simulation box of the full system of the 1968 HA-AB complex. 
The protein had at least a 10 Å buffer in every direction of the rectangular periodic box. 
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Figure 12: Ribbon representations of mono-subunits of the homo-trimmeric, hemagglutinin, 
glycoprotein of the original 1968 HA, mutated 1999 HA, the 1968 HA-AB complex (from right to 
left). The blue and red ribbons show the two distinct chains found in a mono-subunit of HA. The 
magenta and cyan ribbons in HA-AB complex represent the light and heavy chain, respectively. The 
yellow amino acids in the 1999 HA represent the mutated residues. The bottom box is a representation 
of the simulation box of the full system of the 1968 HA-AB complex (the complex is represented by 
red ribbons and water by blue wires). The total system size is 188605 atoms. 
 
The preliminary pI calculations performed for both starting structures using the 
WebServer H++, Sodium ions/Chloride counter ions added to the HA/HA-AB complex 
and the total amount of water molecules added are shown in Table 2 below. The antibody 
seems to be positively charged as it causes the complex to be more positive when 
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compared to the HA alone. E.g., for the 1968 HA, charge at pH 6.5 is -3, when antibody 
is added to form complex, total charge is +3. Earlier HAs have a more negative total 
charge at pH 6.5 and lower isolectric point. The isolectric point and the total charge at pH 
6.5 increases with year progression (lowest 1968, highest 1999). Interestingly, in the 
1968 HA-AB complex, the HA is an anion while the AB is a cation, the proteins are thus 
complementary and encourage binding. However by 1985, both proteins are cations and 
binding would thus not be favorable. There also appears to be a change in protonation 
state of some of the antibody’s amino acids upon HA, AB binding (HIS 196 and HIS 
204); when in isolation the AB appears to have a + 8 charge, however, when in complex, 
it has a +6 charge.  
Table 2: The preliminary pI of starting structures for both the HA and their complexes calculated using 
the WebServer H++ and total amount of waters and sodium/chloride ions added.  Sodium ions/Chloride 
counter ions were added to the HA-AB complex using the columbic grid of the LEaP module of AMBER, 
and water added using an equilibrated TIP3P water in a rectangular periodic box as a building block. The 
antibody seems to be positively charged as it causes the complex to be positive when compared to the HA 
alone. Earlier HAs had a more negative total charge at pH 6.5 and lower isolectric points. 
YR OF 
Hong Kong/ 
H3N2 
HAEMAGLUTININ ALONE HAEMAGLUTIN-AB COMPLEX 
 pI Total 
charge at 
pH 6.5 
N.O/Type 
of ions 
added in 
leap 
Total 
number of 
H2O added 
in leap 
pI Total 
charge at 
pH 6.5 
N.O/Type 
of ions 
added in 
leap 
Total 
number of 
H2O added 
in leap 
68 6 -3 3 Na+ 
24996 
8 3 3 Cl- 
58169 
69 6 -3 3 Na+ 
24995 
8 2 2 Cl- 
58168 
74 7 0 0 
25030 
8 4 4 Cl- 
58091 
75 7 1 1 Cl- 
25025 
8 5 5 Cl- 
58086 
85 9 6 6 Cl- 
26468 
9 9 9 Cl- 
60018 
92 8 5 5 Cl- 
26461 
9 9 9 Cl- 
60001 
99 9 6 6 Cl- 
26945 
9 13 13 Cl- 
59978 
AB 9 6 8 Cl- 
17255 
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 To obtain reliable estimates of absolute binding free energies, the average values 
calculated by MM-PB(GB)SA had to be converged. After the equilibration run, density, 
temperature, pressure and total energy data for all HA complexes were extracted from the 
output files and combined to form continuous plots. It was confirmed that the systems 
were equilibrated as all the values appeared to converge and the temperature had reached 
the desired 300 K after 20 ps of equilibration (Figure 13). The average density was close 
to the expected 1.0 gm/ml, which is appropriate for a protein solution, and the average 
pressure was approximately 1 atm. Based on these plots it appears that the production 
runs were stable and well behaved.
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Figure 13: The plots of the density, pressure and temperature (left) and potential (Eptot), kinetic (Ektot) and total Etot energy (right), 
versus time, of the 1968 and 1969 HA-AB complex equilibration runs. The system was equilibrated in two stages (with the protein 
molecules fixed first and then the entire system). Temperature was increased gradually from 10K to 300 K while maintaining constant 
pressure. Berendsen algorithm was used to maintain system at its assigned temperature (300K). The graphs show that the systems had 
been brought safely from 10K up to 300 K after 20 ps of run time and the density of the water box adjusted to  ~1.0 grams/L. The values 
on the Y-axis on the graphs on the right represent the temprature (K), pressure (atm) and density (gm/L), depending on what property is 
being followed. The values on the Y-axis on the graphs on the left represent energy (kcal/mol). 
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         To further investigate the extent of equilibration, the root mean square deviation 
(RMSD) in C -α position compared to the starting structure was determined as a function 
of time. A typical RMSD plot is shown in Figure 14 for the simulation of the 1985 
complex. It seems clear that there is a significant conformation shift occurring at about 
250 ps. Based on the separate superposition of either just the antibody or just the HA 
(also shown in Figure 14), it is clear that the conformational shift is due to HA not the 
antibody. The B factor plot and RMSD plots of the 85 HA-AB complex seemed to 
indicate that the AB was more flexible than HA and while the AB had reached an 
equilibrated conformation state at around 100ps, HA had not (Figure 14). To further 
clarify the nature of the conformational shift, a B-factor plot was prepared and is included 
in Figure 14. For the HA, which represents residues 1- 566 in this plot, the most flexible 
region is around residue 322 which suggests a change in conformation of the long helical 
stalk which is far from the antigen binding site.      
  
 
 
Figure 14: B-factor plot and backbone RMSD plots of the 1985 HA-AB complex. B-factor plot (top left) and back bone RMSD plots of the 1985 HA-
AB complex (top right), AB from complex (bottom left) and HA from complex (bottom right). The B factor shows that the antibody is more flexible 
than the HA. The RMSD plots show that while the AB had definitely reached equilibrium, HA had not.
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   The MM-PB(GB)SA method was used to average contributions of gas-phase 
energies and solvation free energies calculated for snapshots of the HA–AB complex as 
well as the unbound components, which were extracted from MD trajectories. The 
binding free energy was obtained as the difference between the free energy of the 
complex and the individual molecules. In our case, all water molecules were stripped, as 
were all counter ions. Table 3 contains a free energy analysis showing energetic 
contributions to the binding free energy of HA-AB, obtained for 60 snapshots of equal 
spacing from the 500 snapshot MD trajectories of the HAs. Only 60 snapshots were 
selected to ensure the binding energy calculations finished in a reasonable time frame i.e. 
three days for each complex. The gas-phase energies included coulomb, van der Waals, 
and internal energies. The solvation free energy is obtained as sum of a solvent-accessible 
surface-dependent nonpolar contribution and a polar contribution from solving either the 
PB or GB equations (see, Figure 9). In all cases ∆EINT is negligible which indicates 
conformational changes upon binding did not lead to any internal strain. 
 
  
 
Table 3: Specific energy contributions to the binding free energy in kcal mol-1. Numbers in brackets represent standard deviations. ∆EELE, electrostatic 
molecular mechanical energy contribution calculated from the Coulomb potential; ∆EVDW, van der Waals distance-dependent interaction energy 
calculated from the Lennard-Jones potential; ∆EINT is the internal energy from bonds, angles and torsions; ∆EMM , total molecular mechanical Energy 
(from generated snapshots); ∆GSolv, total solvation energy; ∆GGB HCT, electrostatic solvation contribution from solving  the Generalized  Born equation, 
using the GB HCT model ( HCT refers to the GB method used (IGB=1). Further descriptions of this method may be found in the AMBER 7 manual); 
∆GPB, electrostatic solvation contribution from solving the Poisson Boltzmann equation; ∆GBind(GB)/∆GBind(PB, binding free energy from GB or PB 
method respectively. 
Free Energy Analysis (Kcal mol
-1
) Binding of Influenza HA to the 68 HA antibody using the MM-
PB(GB)SA Method
 
 
A/Hong 
Kong/l/68(H3) 
A/Hong 
Kong/l/69(H3) 
A/Hong 
Kong/l/74(H3) 
A/Hong 
Kong/l/75(H3) 
A/Hong 
Kong/l/85(H3) 
A/Hong 
Kong/l/92(H3) 
A/Hong 
Kong/l/99(H3) 
∆EELE  -272.11 31.06) -271.4(22.97) -19.06(21.63) 22.56(30.95) 98.07(27.96) 80.54(17.78) 297(12.61) 
∆EVDW -84.58 (3.97) -83.32(6.21) -80.68(4.84) -87.98(5.27) -94.61(5.53) -85.77(2.41) -95.14(5.62) 
∆EINT 0.01 (0.02) 0.02(0.02) 0.01(0.02) 0.02(0.02) 0.01(0.01) 0.04(0.04) 0 
∆EMM -356.67(30.46) -354.7(22.35) -99.73(22.33) -65.4(30.34) -3.47(26.77) -5.19(16.58) -201.86(10.73) 
 
 
       
∆∆Gnp -10.00 (0.27) -10.12(0.43) -9.19(0.34) -9.79(0.39) -10.69(0.34) -10.08(0.27) -10.41(0.56) 
∆∆GPB 322.50(28.80) 306(18.76) 144.29(18.83) 120.89(28.09) 85.71(20.95) 56.23(21.84) -72.49(17.73) 
∆∆GSolv 312.51(28.76) 295.87(18.63) 135.1(18.68) 111.09(27.86) 75.02(20.79) 46.15(21.63) -82.9(17.56) 
∆∆GPB,Elec 50.39 (12.83) 34.59(15.9) 125.23(11.83) 143.45(10.90 183.78(15.28) 136.78(6.49) 224.51(14.98) 
∆GBind(PB) -44.17(11.75) -58.83(13.04) 35.37(11.35) 45.69(10.53) 78.49(14.24) 40.96(8.72) 118.96(10.7) 
 
 
        
∆∆Gnp,GBHCT  -12.06 (0.36) -12.23(0.57) -10.99(0.45) -11.79(0.52) -12.97(0.45) -12.17(0.36) -12.61(0.74) 
∆∆G
 GB
HCT
 
302.00(28.17) 300.65(20.48) 66.53(18.29) 26.53(26.49) -42.72(24.88) -27.72(15.56) -224.51(7.26) 
∆∆GSolv, GBHCT 289.94(28.18) 288.42(20.5) 55.54(18.13) 14.75(26.18) -55.69(24.68) -39.89(15.25) -237.12(7.46) 
∆∆GGB,Elec 29.89 (5.27) 29.25(7.87) 47.47(5.98) 49.1(6.28) 55.35(6.14) 52.82(2.34) 72.49(7.28) 
∆GBind(GB) -66.73 (5.49) -66.28(5.3) -44.19(6,54) -50.65(5.64) -52.22(4.89) -45.08(3.08) -35.25(5.44) 
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To test the internal consistency of the computations, binding free energy 
calculations were repeated using only 5 snap shots of trajectories from 1969 HA. A 
comparison of the results with values obtained for 60 snapshots indicates essentially 
identical binding energy values (64.88 ± 6.1 kcal mol-1 vs. 66.28 ± 5.3 kcal mol-1) 
Figure 15 shows the different energy contributions to the binding energy. ∆EELE 
(electrostatic component from solute) is initially highly favorable for the 1968 HA 
complex but becomes very unfavorable in later years. This reflects the change in net 
charge of the HA as a result of the mutations. ∆EVDW (van der Waals component) favors 
binding in all complexes and is fairly constant. ∆EINT (internal component) and ∆Gnp  
(non-polar/non electrostatic contributions to solvation energy) have very little 
contribution; ∆GGB or ∆GPBHCT (electrostatic contribution to the solvation energy 
determined by the GB/PB equation), which are initially highly unfavorable, decrease with 
time thus partially balancing the unfavorable change in ∆EELE. The 1992 HA (which also 
did not follow the overall increase in number of mutations trend when compared to the 
amount of mutations in the previous year) also showed a difference in trend in ∆EELE and 
GGBHCT. The value becomes slightly less positive for ∆EELE than the previous year while 
all the other HA values were more positive than the previous year. In addition, the value 
became slightly less negative for GGBHCT than the 1985 HA while all the other GGBHCT 
HA values were more positive than their prior year. 
 
 
  
 
 
Figure 15: The different energy contributions to the binding energy. ∆EELE (electrostatic component) progressively decreased favor of binding; ∆EVDW 
(van der Waals component) favors binding in all viruses; ∆EINT (internal component) and ∆Gnp  (non-electrostatic contributions to solvation energy), 
very little contribution; ∆GGB/ ∆GPB (electrostatic contribution to the solvation energy determined by the GB/PB equation), decreased contribution with 
time. HCT refers to the GB method used (IGB=1). 
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To show the trend of binding energy with year progression, as calculated by the 
MM-GBSA method, a graph of binding energy versus time (year) was constructed 
(Figure 16). The least negative binding energy (lowest antibody affinity) was displayed 
by the 1999 HA while the original HA from the 1968 HA had the highest negative 
change in binding energy (highest antibody affinity). This trend is consistent with the fact 
that the antibody is specific for the 1968 HA and that later years can presumably escape 
the antibody. 
A graph was also constructed to show  the trend of binding energy with year 
progression as calculated using the MM-PBSA  method (Figure 17). A similar pattern of  
general decrease in binding affinity is seen with the  least negative binding energy change 
(lowest antibody affinity) by the 1999 HA  but the the most negative change in binding 
energy (highest antibody affinity) was by the 1969 HA mutant rather than the 1968  HA 
as might be expected. However, the difference in binding energy between 1968 and 1969 
is barely larger than the standard deviation in the binding energy calculation and 
therefore the difference may not be significant. 
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Figure 16: Graph showing change in free binding energy with increase in time/mutations, as calculated by MM-
GBSA. The 1968HA had the highest negative free energy change (-66.73 ± 5.49 kcal mol-1) while 1999 HA had 
the lowest (35.25 ± 5.44 kcal mol-1). The error bars indicate standard deviation. 
 
 
Figure 17: Graph showing the trend of binding energy with year progression as calculated using the MM –
PBSA. The least negative binding energy change (lowest antibody affinity) was by the 1999 HA (118.96 ± 
10.7 kcal mol-1) while the 1969 HA (58.83 ± 13.83 kcal mol-1) had the most negative change in binding 
energy (highest antibody affinity). The error bars indicate standard deviation.    
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 DISCUSSION  
 
 
 
 
The sites of amino acid substitution in natural variants of HA from Hong Kong 
H3 subtype viruses that were analyzed were scattered throughout the HA.  However, as 
suggested in various studies, most substitutions coincided with HA epitopes on proposed 
antigenic sites that surrounded the conserved host-receptor binding site, while mutations 
in the stalk were much less frequent 34. Taking into account that the antibody footprint is 
larger than the receptor binding site, this is a very efficient way of preventing 
neutralization of the influenza virus as it reduces binding of antibodies that target this 
binding site without compromising its receptor binding function; which allows new virus 
subtypes to spread within non immune species. That most of the “fixed changes” (i.e. 
changes that were retained in HAs of isolated viruses in subsequent years), involved 
residues on the surface membrane–distal globular domain of HA that surround the 
receptor binding site whereas most of those that are not retained were found to be buried, 
was also the general trend found in the HAs of the seven strains of the influenza viruses 
analyzed. Fixed substitutions are thought to be naturally selected because they prevent 
antibody binding 35. 
The fact that simulations of all the seven HA-AB systems were carried out with 
exactly the same computational procedures, allowed analytical comparisons to be made 
between the binding energetics of  Hong Kong HA isolates to the 1968 HA antibody, 
over a period of twenty years. In line with the results of other studies 3, 44, 45, 92, binding 
free energy became less favorable with increase in mutations, from 1968 to 1999 (-66.73 
to -35.25 kcal mol-1). Fleury et al 46 also found that a HA wild type specific antibody still 
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bound to three escape mutant HAs, but with a much reduced affinity i.e. between Kd 4 × 
10−6 M and 5 × 10−7 M. This was significantly lower than its affinity for the wild-type 
HA (Kd 10−9 M) 3. However, the results of the MM-PBSA study show that there was no 
increase in antibody binding affinity after twenty years of mutations. The 1968 HA had 
most favorable change in free energy binding energy through the twenty years (-66.73 
kcal mol-1). This may be due to continuous pressure by the original 1968 antibody on new 
mutated viruses, in addition to their own HA specific antibodies. That is, if any of the 
earlier 1968 HA viruses were still circulating in the human population, antibodies against 
it would also be present; new viruses would therefore try to mutate to prevent strong 
binding by these antibodies as well as their most immediate-specific antibody.  
Interestingly, despite the overall positive trend of decrease in energy, the sequential 
mutations showed a significant fluctuation in binding energy. This might be additional 
proof that the mutations are random but self-corrective in nature. Sites where amino acid 
changes can alter antigenicity are so limited that in some strains key amino acids in these 
sites changed for the second time as evolution proceeded while some reverted back. 
Presumably, at any stage in the evolution of a viral subtype, several different strains may 
be circulating simultaneously and the combination of changes that are most favorable to 
the virus would be ones that are preserved during evolution 17, 31. Successful strains 
dominate and thus become progenitors for future generations; these are ones that have 
HAs that don’t bind too tightly to currently available antibodies. 
  A search of available literature did not result in any articles that indicated any 
general preference of amino acid by a larger or different side chain for mutations. This 
was the case in this study. However, from a quick look at the types of mutations of the 
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HAs analyzed, it seems there were was a general conservation of mutations in terms of 
polarity i.e. a polar amino acid was substituted with another polar amino acid. In addition 
it has been suggested that oligosaccharide attachment also prevents antibody recognition 
93
. This could be due to the inability of carbohydrate covered protein side chain surfaces 
to induce antibodies, as the carbohydrates side chains are synthesized by cellular 
enzymes and are thus “antigenically self”. They thus mask regions of proteins from 
recognition by antibody. It should be noted that the lack of information on the crystalline 
structure of oligosaccharide attachments in HA herein studied, implies that the analysis of 
these attachments were not included as part of this study. This is despite the fact that 
since the beginning of the Hong Kong pandemic period in 1968, a study of the recent 
changes in influenza virus showed an increase in the number of oligosaccharide 
attachment sites (especially on the membrane distal domain of HA). While the Hong 
Kong HA monomer in 1968 had a total of three attachment sites (at position 81, 165, 
285), this number had increased to eight by 2005 (63, 122, 126, 133, 144, 165, 246 and 
285) 23, 94. A study of the role of oligosaccharide attachment in reduction in binding 
affinity would be beneficial in better predicting the trend in amino acid substitution 
during HA antigenicity. 
Detailed analyses of the binding energetics of influenza HA to the 1968 antibody 
allows better understanding of the contribution of different energy terms to the binding 
free energy. The association of the antibody and HA is driven by highly favorable van der 
Waals interactions (∆EVDW), the most important and consistent complex formation 
favoring term (Figure 15). This being the case, it is surprising to note that its contribution 
is constant and does not decrease with time to allow the virus to more easily escape 
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antibody binding. In all seven HA-AB complexes investigated, the van der Waals 
interactions for HA binding were between -80.6 and -94.6 kcal mol-1. In line with the 
results of this work, the non-covalent association has been found to be driven by 
favorable van der Waals energies in several MM-PBSA studies 75 . 
In contrast to van der Waals energies, electrostatic energies contributed unequally 
to the binding of the HA virus strains to the 1968 antibody. That the unfavorable 
electrostatic solvation is compensated, but not fully, by favorable electrostatic protein–
ligand interactions has been observed in several earlier ligand-binding studies and seems 
to be a general phenomenon 75, 76. In agreement with earlier computational ligand binding 
studies, the solvation electrostatic energies (∆∆Gelec, PB/ GB) are mostly unfavorable for 
binding, but the degree at which the energy disfavors binding, decreases with year 
progression.  For example by 1999 the solvation electrostatic energy favors binding 
compared to 1968 when it disfavors binding. The exact opposite effect is seen with solute 
electrostatic energies (∆∆EELE). While in the 1968 and 1969 HA the energies favor 
binding, by 1999 the energies disfavor binding. Thus, electrostatic interactions determine 
the specificity in the binding of influenza HA to antibody. Solvent effects are most 
important when  the binding between HA and antibodies is less strong. Looking back at 
the total charges of the modeled HAs (Table 1), mutations seem to favor amino acids that 
make the HA more positively charged (3 for 68 vs. +6 for 99). This could account for the   
∆EELE, electrostatic molecular mechanical energy contribution calculated from the 
Coulomb potential becoming more positive with year progression (thus disfavoring 
complex formation). Less favorable solute energies due to the preference of more 
positively charged amino acids during mutation could hint to a strategy used by influenza 
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viruses to escape antibody binding. Analyses of more viruses should provide more 
evidence of this trend 95. Similar to other studies 74, 77, both internal energy (∆EINT) and 
non-electrostatic energies contribution to solvation (∆∆Gnp) are very small and contribute 
minimally to the complex formations. 
The MM-GBSA calculations of the study seem to over estimate the relative free 
binding energy of influenza HA to antibody when compared to the limited available 
experimental values (12 kcal mol-1 3) and other  free energy computational studies (36 vs. 
66 kcal mol- 196). However, in view of the fact that the accuracy of absolute binding free 
energy calculations depends on a delicate balance of different energetic and entropic 
contributions, the calculated binding free energy can still be considered close to the 
experimentally determined one. In addition, for the purpose of this study, we were more 
interested in the trend of binding energies (qualitative) than the exact values 
(quantitative). Therefore, if we assume that all values were over estimated by the same 
degree, the conclusions that the trend shows a decrease in negative binding energy with 
increase in mutations, remains valid. It should also be noted that the study involved 
stimulation of the HA monomer and not the whole homotrimmer, as it is found in nature. 
This could have also contributed to the difference in results. 
Calculations of the binding free energies of the HA–AB for snapshots extracted 
from the single complex trajectory versus three trajectories calculations might have 
contributed to the difference in values from those that have previously described in 
experiments. The method was chosen because it is less time consuming than using 
snapshots from three separate trajectories and potentially requires less sampling, because 
all of the intramolecular energies cancel when calculating the association energy. Related 
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studies applying MM-PB(GB)SA for the prediction of absolute binding affinities have 
shown good agreement between values calculated for snapshots extracted either from the 
complex trajectory or from all three trajectories.  However, Gohlke et al 74, 97 showed that 
the single trajectories approach is only completely successful, if no conformational and 
dynamical changes upon complex formation occur in the binding partners. In the case of 
the influenza HA although there has been some evidence of conformational change upon 
binding 48, 98, this has not been proven. RMSD and B-Factor plots made of the 1968 HA 
and 1985 HA (Figure 14) suggest that although the antibody is more flexible than the HA 
during the simulation, the HA is undergoing a more significant conformation shift and is 
taking longer to equilibrate. If conformational change does take place, it would account 
for some of the disparity between the calculated binding free energies and the 
experimental values available.  
Another minor complication that resulted was that despite a similar qualitative 
pattern in binding energy data being realized in both GB and PB methods (which as 
mentioned earlier is what was most important in this study), a difference in quantitative 
data was obtained by the GB and PB method. The difference in values of binding 
energies by the PB or GB method results from a difference in calculation of the 
electrostatic energies by solving the respective equations, as shown in Table 3. The 
difference could be due to choice of parameters. Upon HA-AB complex formation, polar 
and charged residues become buried in the binding interface. Modeling of the desolvation 
penalty and correctly estimating screened electrostatic interactions between both proteins 
is therefore crucial for the accurate estimation of binding affinity. Free energy 
contributions can be calculated by solving the Poisson-Boltzmann equation using radii 
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from the PARSE parameter set (PB-linearized or PB-non-linearized) Bondi radii or by 
solving the General Born equation by applying generalized Born models of Jayaram et al. 
(MGB/GB JSB) 99, Onufriev et al. (GBOBC) 100, and Tsui et al (GBHCT) 101. The different 
models using the different parameter sets produce different results as shown by Golkhe 
and Case 74 who tested the internal consistency and the model dependence influence of 
different continuum solvation models on the absolute binding free energy of Ras-Raf . 
They found that calculated absolute binding free energies strongly depend on the applied 
solvation model and were within a range of 6.2 kcal mol-1 (from PB equation using an 
linearized PARSE parameter) to -49.4 kcal mol-1 (from GB equation using Tsui et al 
(GBHCT) solvation model). The results obtained using different GB models in connection 
with a solvent-accessible surface area-dependent term (to estimate nonpolar solvation 
energies) overestimated the binding affinity of Raf towards Ras, whereas PB calculations 
yielded binding free energies that were either too positive or too negative, depending on 
the atomic radii applied. Studies have shown that using the GBOBC would result in the 
results that are most similar to PB results. This is not unexpected, because GBOBC has 
been modified to give better agreement between PB and GB results for RAS-RAF 
binding. It is thought that PB gives values that are closest to experimental values. No 
studies were found that showed the same agreement in values between the PB and GB 
method when using the GBOBC model in other protein-antibody systems. In this study, the 
GBHCT model was chosen for the GB calculation, as it was the only model that worked 
with the current parameter set and system set up. This could be due to the AMBER 
version used as some of the GB models require later versions of AMBER. 
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Further testing and parameterizations across large sets of systems with different 
properties will be necessary to probe the transferability of the protocols and further 
improve parameters for influenza. It will be interesting to evaluate the influence of recent 
developments in the field of polarizable force fields and continuum solvent descriptions 
on the outcome of these calculations.  
Even though the basic idea is simple, the art of MD was challenging in practice as 
the results of a MD simulations can only be as good as the governing force field. The 
functional forms of force fields employed in the molecular mechanics were a compromise 
between accuracy and computational efficiency. For example, that the calculated binding 
free energies were larger than those obtained by experiment may have also been caused 
by the short time scale of the MD simulations. Also due to the computational demand, the 
calculations were reported for 60 snapshots from the set of 500 extracted from 
trajectories. Studies done using only a subset of snapshots did not lead to a significant 
change of the calculated binding free energy compared to the one obtained for the total 
set; but there was an increase in standard deviation. These simplifications meant that the 
MD simulations of the trajectories needed for energy analyses was by today’s standards a 
computationally inexpensive tasks, making screening of the multiple influenza complexes 
feasible in a limited amount of time. 
Other various techniques that could be used to predict relative binding free 
energies of protein-protein association include free energy perturbation (FEP) 95 and 
linear interaction energy (LIE). FEP and other similar computer simulation techniques, 
such as thermodynamic integration, offer a rigorous statistical mechanical way to 
calculate free energies of binding. However, for the purpose of this study, they were not 
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conducive as they also suffer from long computational times and technical difficulties 
associated with creation and annihilation of atoms and have typically been used for single 
mutation studies. Also for an LIE calculation experimental binding data is needed to fit 
against in order to do the calculation, which is rarely available 102. Compared to the more 
traditional Free Energy Perturbation (FEP) simulations, the MM–PBSA method is a 
slightly less accurate but a considerably faster approach. However, it is important to note 
that although the FEP methods can be applied reliably only to relatively small mutations, 
it in favorable cases provides free energies at chemical accuracy (i.e. within 1 kcal mol-1 
from experiment). However, this accuracy would not have been beneficial in the case of 
this study since the computing time for similar study using FEP would be too expensive 
and this study involved doing multiple mutations.  
The success in calculating and summarizing the relative binding free energies of 
the HAs indicates that the MM-PBSA method is a fairly reliable tool to investigate virus-
antibody interaction that is not too computer time expensive. The results show that 
antigenic drift of influenza viruses caused by gradual mutations to the HA gene 
continually produce immunologically distinct strains that bind less tightly to the specific 
antibody.  Since the emergence of such new drift variants underlines the importance of 
influenza virus surveillance, the effectiveness of influenza vaccinations may be greatly 
reduced when there is a significant antigenic mismatch between vaccine strains and 
circulating viruses 103. Although our data does provide a bit more insight on the trend of 
mutations, neither antigenic nor energetic analysis alone can give sufficient information 
on the route of evolution of influenza viruses. Therefore, additional antigenic as well as 
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genetic characterization of currently circulating influenza viruses is required for 
determining the most appropriate composition of new influenza vaccines. 
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